JPM vs LPLA

JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.

LPLA exhibits a stable financial foundation with a Piotroski F-Score of 5/9, though it currently trades at a significant premium to its Graham Number ($128.01) and Intrinsic Value ($151.65). The company demonstrates elite operational consistency, having beaten earnings estimates for nearly 25 consecutive quarters, and possesses a highly attractive PEG ratio of 0.42. However, the valuation gap, combined with bearish insider selling and a 0/100 technical trend, offsets the strong growth metrics. The stock appears to be a high-quality compounder that is currently overpriced based on deterministic value models but potentially undervalued based on forward-looking growth projections.